SARMs
RAD 140
Compound ID
Testolone
Dosage
10–20 mg/day
Concentration
10 mg/tablet
Form
100 Tablets × 10 mg
Half-life
Approximately 16–20 hours
Properties
Product overview
Dragon Pharma RAD-140 10mg — High-Affinity SARM for Rapid Lean Hypertrophy, Strength Surges & Neuroprotective Potential
Dragon Pharma RAD-140 10mg, scientifically designated as Testolone, represents one of the most potent non-steroidal selective androgen receptor modulators in the contemporary performance enhancement landscape. Originally synthesized by Radius Health for therapeutic applications including muscle wasting, osteoporosis, and hormone-sensitive malignancies, this research compound has transcended its clinical origins to become a cornerstone of advanced physique protocols. Characterized by an exceptionally high binding affinity for androgen receptors and an anabolic potency that rivals traditional testosterone in preclinical models, RAD-140 offers athletes a mechanism for substantial lean mass accretion and explosive strength gains while theoretically minimizing activity in reproductive tissues. Dragon Pharma's precisely manufactured 10mg oral tablets undergo rigorous independent verification, delivering a pharmaceutical-grade research tool for informed users who demand analytical transparency and dosing consistency in their supplementation protocols.
What is Dragon Pharma RAD-140?
RAD-140 is a non-steroidal selective androgen receptor modulator that functions as a high-affinity ligand for androgen receptors in skeletal muscle and osseous tissue. Unlike anabolic steroids, which indiscriminately activate androgenic pathways across prostate, skin, sebaceous glands, and hepatic systems, Testolone was engineered to selectively stimulate anabolic activity in muscle and bone while exhibiting minimal agonism in reproductive organs. This tissue selectivity underpins its favorable therapeutic index, though it is critical to emphasize that RAD-140 remains a research chemical without FDA approval for human consumption. The compound is administered orally with an estimated elimination half-life of 16–20 hours, supporting convenient once-daily dosing. Dragon Pharma's 10mg formulation provides a precisely quantified, analytically verified vehicle for researchers and advanced athletes exploring this compound's potent anabolic and neuroprotective properties.
Key Benefits / Effects
- Rapid Lean Hypertrophy: Considered among the most anabolic SARMs in preclinical literature, RAD-140 stimulates robust protein synthesis and nitrogen retention, supporting significant lean mass gains within single-cycle timeframes when combined with resistance training and adequate protein intake.
- Explosive Strength Amplification: High-affinity androgen receptor activation in skeletal muscle improves neuromuscular transmission efficiency and contractile force generation, enabling heavier compound lifts and more productive high-intensity training sessions.
- Body Recomposition Support: While not directly lipolytic, the compound increases metabolic rate through lean tissue accretion and supports a harder, more defined aesthetic—particularly visible during hypocaloric phases or cutting protocols.
- Accelerated Recovery Kinetics: Enhanced anabolic signaling reduces muscle protein breakdown between sessions, with users frequently reporting diminished delayed-onset muscle soreness and faster return to baseline performance capacity.
- Neuroprotective Potential: Preclinical investigations have demonstrated that RAD-140 may reduce neuronal cell death from amyloid-beta toxicity, suggesting possible applications beyond musculoskeletal enhancement—though human neurological data remains in early stages.
How Dragon Pharma RAD-140 Works
Testolone initiates its effects through selective, high-affinity binding to androgen receptors within skeletal myocytes and osteoblasts, triggering a conformational shift that facilitates nuclear translocation and subsequent transcription of anabolic genes. This genomic activation upregulates muscle-specific protein synthesis, satellite cell recruitment, and myonuclear domain expansion while simultaneously supporting bone mineral density maintenance. The compound's design philosophy emphasized reduced agonist activity in prostate and uterine tissues compared to testosterone, theoretically lowering the risk of benign prostatic hyperplasia and virilization. In neural tissue, preclinical models suggest RAD-140 may activate neuroprotective pathways that mitigate excitotoxicity and amyloid-induced cellular damage. The net physiological outcome in athletic contexts is a potent anabolic environment conducive to rapid strength-to-mass ratio improvements, though this mechanism simultaneously exerts significant negative feedback on the hypothalamic-pituitary-gonadal axis that cannot be overlooked.
Usage Information
Dragon Pharma RAD-140 is supplied as 10mg oral tablets with an estimated pharmacokinetic half-life of 16–20 hours, making once-daily administration sufficient for stable receptor activation. Novice users should initiate at 5–10mg daily to assess individual tolerance and sensitivity to suppression. Intermediate practitioners typically employ 10–20mg daily, representing the most common effective range for significant hypertrophic and strength outcomes. Advanced users may explore 20–30mg daily, though doses exceeding this threshold significantly amplify suppression risk, hepatic strain, and cardiovascular stress without proportional anabolic returns. Standard cycle duration spans 6–8 weeks, with some experienced users extending to 8–10 weeks under comprehensive health monitoring. Time off between cycles must equal or exceed the active cycle length to permit full hypothalamic-pituitary-gonadal axis recovery. Dosing may occur at any consistent time of day, though evening administration should be avoided by individuals sensitive to stimulatory or insomnia-inducing effects. Alcohol consumption is contraindicated during use due to additive hepatic burden.
Quality & Manufacturing
Dragon Pharma implements rigorous quality-assurance frameworks across all production stages, with independent third-party laboratories analyzing each RAD-140 batch for identity, concentration accuracy, and contaminant absence. In the unregulated research chemical marketplace, where Testolone products are frequently underdosed, mislabeled, or contaminated with prohormones and anabolic steroids, this level of analytical transparency is essential for user safety and protocol predictability. Dragon Pharma's commitment to verified potency ensures that each 10mg tablet delivers the exact pharmacological payload required for meaningful research outcomes, eliminating the uncertainty that plagues generic or unverified sources. Athletes and researchers integrating this compound into their protocols can do so with confidence in both the product's authenticity and its manufacturing integrity.
Possible Side Effects / Safety Information
- Significant Testosterone Suppression: RAD-140 exerts potent negative feedback on the hypothalamic-pituitary-gonadal axis, reducing luteinizing hormone and follicle-stimulating hormone secretion even at conservative doses. Post-Cycle Therapy is mandatory.
- Hepatic Enzyme Elevation: Oral administration may produce elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Rare cases of drug-induced liver injury have been reported with SARM-class compounds.
- Dyslipidemia: The compound can depress high-density lipoprotein (HDL) cholesterol while elevating low-density lipoprotein (LDL) cholesterol and triglycerides, increasing cardiovascular risk factors during active use.
- Neuropsychological Disturbances: Some users report increased anxiety, irritability, or insomnia—likely related to the compound's stimulatory properties and hormonal fluctuations.
- Androgenic Dermatological Effects: Despite its selectivity, genetically predisposed individuals may experience acne vulgaris or accelerated androgenic alopecia at higher doses.
- Cardiovascular Red Flags: Users should discontinue immediately and seek emergency medical attention if experiencing chest pain, dyspnea, severe hypertension, or arrhythmia.
- Hepatic Warning Signs: Jaundice, dark urine, clay-colored stools, or severe right-upper-quadrant abdominal pain indicate potential hepatotoxicity requiring urgent clinical evaluation.
- Ocular Symptoms: Any sudden vision changes, persistent visual tinting, or difficulty adjusting to light conditions warrants immediate cessation and ophthalmological assessment.
Why Choose Dragon Pharma RAD-140?
Navigating the research chemical landscape requires discernment, particularly when product purity directly influences both efficacy and safety outcomes. Dragon Pharma eliminates the ambiguity endemic to unverified Testolone sources through independent analytical verification of every production batch. This commitment to transparency ensures that users receive precisely dosed, uncontaminated RAD-140 rather than mislabeled prohormones or inert fillers. For advanced athletes and researchers seeking one of the most anabolically potent SARMs available—capable of delivering steroid-like strength and lean mass outcomes within a selective receptor framework—Dragon Pharma RAD-140 offers a verified, consistently manufactured platform that prioritizes both performance potential and responsible harm reduction.
Any idea when this and S4 will be in stock? Thanks
Product FAQ
Questions, answered
Preclinical models indicate that RAD-140 possesses an anabolic potency comparable to or exceeding testosterone on a milligram-for-milligram basis, particularly in skeletal muscle tissue. However, its selectivity theoretically reduces androgenic activity in prostate and skin tissues. The trade-off is that RAD-140 still produces significant testosterone suppression, liver stress, and lipid disruption—risks often underestimated by those assuming "SARM" equates to "safe." Traditional steroids offer more predictable human pharmacokinetic data, whereas RAD-140 remains an experimental compound with limited long-term safety profiles.
First-time users should begin with 5–10mg daily for a 6-week cycle. This conservative approach allows accurate assessment of individual tolerance, suppression severity, and hepatic response before considering escalation. Beginners should never exceed 10mg daily or extend beyond 6 weeks. Comprehensive blood work—total testosterone, LH, FSH, liver enzymes, and lipids—should be obtained before initiation and repeated at week 4 to monitor physiological changes.
Yes. RAD-140 suppresses luteinizing hormone and follicle-stimulating hormone at doses as low as 5–10mg daily, leading to downstream testosterone deficiency. Without pharmaceutical recovery intervention, users risk prolonged hypogonadism, rapid loss of cycle gains, lethargy, depression, and diminished libido. A standard PCT protocol includes Tamoxifen Citrate (Nolvadex) at 40/20/20/20mg or Clomiphene Citrate (Clomid) at 50/50/25/25mg over four weeks. Blood work confirming recovered LH, FSH, and total testosterone should precede any subsequent cycle.
Stacking SARMs is generally discouraged because every additional suppressive compound compounds hypothalamic-pituitary-gonadal axis shutdown, hepatic burden, and lipid deterioration. While community discussions frequently mention combining RAD-140 with LGD-4033, S-4, or MK-677, these combinations exponentially increase side effect risk without proportional benefit. If users insist on stacking, they must implement a testosterone base, aggressive liver support, and comprehensive blood monitoring—though the safer approach is to use RAD-140 as a standalone agent with legal recovery supports such as creatine, omega-3 fatty acids, and sleep optimization.
Most users report subjective improvements in training intensity, vascularity, and recovery capacity within the first 7–14 days. Measurable strength increases on compound lifts typically manifest by week 2–3, while visible lean mass changes consolidate between weeks 3 and 6. Because RAD-140 produces dry, high-quality tissue gains rather than fluid-mediated bulk, the physique changes are slower to initiate than with aromatizing steroids but yield more sustainable, aesthetically refined results.
Baseline panels should include total and free testosterone, luteinizing hormone, follicle-stimulating hormone, estradiol, complete blood count, comprehensive metabolic panel (AST, ALT, GGT, bilirubin), and a full lipid profile (total cholesterol, HDL, LDL, triglycerides). Mid-cycle testing at week 4 identifies emerging suppression or hepatic stress. Post-cycle testing 3–4 weeks after cessation—or 3–4 weeks into PCT—confirms hormonal recovery and metabolic normalization. These panels are non-negotiable for responsible use.
While RAD-140 is not a C17-alpha alkylated compound like many oral steroids, it can still elevate hepatic transaminases and, in rare cases, contribute to drug-induced liver injury. Protection strategies include complete alcohol abstinence during the cycle, avoidance of acetaminophen and other hepatotoxic agents, maintenance of adequate hydration, and consideration of liver support supplements such as N-acetylcysteine (NAC) and TUDCA. Any signs of jaundice, dark urine, or persistent right-upper-quadrant pain mandate immediate discontinuation and medical evaluation.
Women can use RAD-140 at significantly lower doses than men, typically 2.5–5mg daily for 4–6 weeks, due to its high potency. While designed for reduced reproductive tissue activity, virilization risk is not zero—voice deepening, clitoral enlargement, and menstrual disruption remain possible, particularly at higher doses or extended durations. Female users should monitor closely for early androgenic symptoms and discontinue immediately upon their appearance. Given the limited human safety data, women should approach this compound with particular caution.
Discontinue immediately and seek medical care if you experience jaundice or yellowing of the sclera, severe chest pain or pressure, difficulty breathing, sudden vision loss or persistent visual disturbances, severe headaches accompanied by hypertension, or signs of an allergic reaction including facial swelling or hives. Less urgent but still important indicators include debilitating lethargy, complete loss of libido, or severe mood disturbances that impair daily functioning.
RAD-140 does not possess direct lipolytic or thermogenic properties. Instead, it supports body recomposition through several indirect mechanisms: increased lean muscle mass elevates basal metabolic rate, improved training capacity allows for greater caloric expenditure during sessions, enhanced nutrient partitioning directs calories toward muscle repair rather than adipose storage, and the dry, non-estrogenic nature of the gains prevents the subcutaneous water retention that masks definition. When combined with a structured caloric deficit, these factors produce a visibly harder, leaner physique.
